International Journal of Scientific and Academic Research (IJSAR) ISSN: 2583-0279
Volume 4, Issue 8, November- 2024
https://ijsar.net
CrossRef DOI: 10.54756/IJSAR.2024.15

Advances in Imaging Analysis for Understanding Brain Disorders

Fatemeh Afrazeh
School of Medicine
Shahid Beheshti University of Medical Sciences,
Tehran, Iran

ABSTRACT
In this paper, we examine advancements in imaging analysis techniques that have deepened our understanding of brain disorders, using modalities like MRI, fMRI, PET, and DTI to analyze brain structure, function, and connectivity. By transitioning from qualitative to quantitative imaging, including volumetric analysis, cortical thickness, and connectivity mapping, we enable more precise, objective assessments that enhance diagnostic accuracy and treatment monitoring. We also explore the field of radiomics, where high-dimensional data extraction is uncovering imaging biomarkers useful for diagnosis and prognosis. Despite these advancements, challenges such as data variability, complexity, and ethical concerns remain. In this paper, we discuss the importance of standardized protocols, data sharing, and AI interpretability to realize the full clinical potential of imaging analysis, with the ultimate goal of transforming care for brain disorder patients through more personalized approaches.

Keywords: Brian Disorders, Medical Imaging, Radiology.

1. INTRODUCTION

Brain disorders, including conditions such as Alzheimer's disease, Parkinson's, schizophrenia, bipolar disorder, and major depressive disorder, represent some of the most challenging and pervasive health issues in society today [1,2]. These disorders have profound impacts not only on the individuals who suffer from them but also on families, caregivers, and healthcare systems worldwide. Cognitive decline, emotional instability, and physical limitations often associated with these disorders can reduce quality of life, increase dependence on long-term care, and lead to considerable economic burdens. In addition, many brain disorders are characterized by progressive or episodic courses, making it challenging to predict outcomes or plan effective treatments. As the global population ages and the prevalence of brain disorders increases, there is an urgent need for better diagnostic and therapeutic tools to support timely, personalized treatment interventions. An early and accurate diagnosis is vital because timely intervention has been shown to improve outcomes and potentially slow disease progression, allowing patients to maintain functional independence for longer periods.

Despite the importance of early intervention, diagnosing brain disorders remains a complex task [3]. Many brain disorders present with overlapping symptoms, and the biological markers that differentiate one disorder from another are often subtle or undetectable using traditional diagnostic methods [4]. Currently, clinicians rely on a combination of subjective symptom reports, clinical examinations, and a few specialized tests. The limitations of these methods underscore the need for more advanced diagnostic approaches. Medical imaging has become an essential tool in both research and clinical settings for understanding and diagnosing brain disorders. By providing a window into the brain's structure, function, and metabolic state, medical imaging offers valuable insights that were previously unavailable. Imaging modalities such as Magnetic Resonance Imaging (MRI) allow for high-resolution structural imaging, enabling the detection of abnormalities in brain anatomy, tissue integrity, and volumetric changes that may indicate disease. Functional MRI (fMRI) is widely used to measure brain activity in response to tasks or stimuli, revealing patterns of activation and connectivity that are often disrupted in psychiatric and neurodegenerative disorders. Additionally, Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT)

allow researchers to study metabolic processes, neurotransmitter dynamics, and receptor binding in the living brain, contributing to a deeper understanding of disease mechanisms.

One of the most promising imaging techniques for studying brain disorders is Diffusion Tensor Imaging (DTI), a specialized form of MRI that maps the diffusion of water molecules within brain tissue. By analyzing the movement of water molecules along white matter tracts, DTI enables researchers to examine the brain's connectivity pathways in detail. This technique is particularly valuable for studying disorders that involve disruptions in brain connectivity, such as schizophrenia and autism spectrum disorders, where changes in white matter integrity and connectivity may underlie cognitive and behavioral symptoms. Each of these imaging modalities provides unique information, and when used in combination, they can offer a comprehensive view of the brain's structure and function. Such a multimodal approach holds promise for improving diagnostic accuracy and for identifying biomarkers that can track disease progression or response to treatment.

In recent years, advances in data and imaging analysis techniques have opened new possibilities for understanding and diagnosing brain disorders [5-10]. Traditional imaging methods primarily relied on qualitative assessments, where radiologists and clinicians would visually interpret images to detect abnormalities. However, the sheer complexity and high dimensionality of imaging data have made it increasingly difficult to rely solely on visual interpretation. Quantitative imaging techniques have emerged to address this challenge, enabling the extraction of numerical data from images that can be used to characterize brain structures, measure volumes, assess cortical thickness, and more. Volumetric analysis, for instance, allows for the precise measurement of brain regions, providing information on brain atrophy patterns that may signal the early stages of neurodegenerative diseases. Network connectivity analysis is another emerging approach, where researchers analyze the functional and structural connections within the brain to understand how different regions interact. Disruptions in these networks are commonly observed in disorders such as depression, schizophrenia, and epilepsy, making connectivity analysis a powerful tool for both diagnosis and research.

Furthermore, the field of radiomics has brought a new dimension to imaging analysis by focusing on the extraction of large amounts of quantitative features from images, including shape, texture, and intensity [11-13]. Radiomics enables a more detailed and comprehensive analysis of imaging data, capturing subtle variations that may be missed by traditional methods. By converting images into high-dimensional data, radiomics has the potential to reveal unique imaging signatures or phenotypes associated with specific brain disorders. These advanced techniques are complemented by computational tools and algorithms that can process and analyze complex data sets with unprecedented speed and accuracy. As a result, imaging analysis has evolved from a primarily qualitative approach to a highly quantitative and computationally driven field, offering new avenues for understanding the intricate changes associated with brain disorders.

The purpose of this paper is to explore these recent advancements in imaging analysis as they relate to the understanding and treatment of brain disorders. Through a comprehensive review of the latest imaging techniques and analysis methods, this paper aims to highlight the ways in which imaging innovations are being integrated into clinical practice and research. By examining both established methods and cutting-edge developments, we seek to demonstrate how imaging analysis can bridge existing gaps in the diagnosis, monitoring, and treatment of brain disorders. Ultimately, this exploration will provide insights into the future of medical imaging in brain health, where advanced analysis techniques have the potential to transform our approach to diagnosing and treating these challenging conditions. By presenting a cohesive view of the state of imaging analysis in brain disorders, this paper aims to contribute to the ongoing dialogue between researchers and clinicians, fostering a deeper understanding of how imaging can be used to improve outcomes for individuals affected by brain disorders.

2. CURRENT STATE OF IMAGING ANALYSIS IN BRAIN DISORDERS

2.1. Overview of Core Imaging Modalities and Their Applications

Magnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI) is widely regarded as the gold standard for structural brain imaging due to its high-resolution, non-invasive capability to capture detailed images of the brain's anatomy. MRI is used extensively to

DOI: 10.54756/IJSAR.2024.15

assess brain tissue integrity, detect abnormalities, and monitor changes over time [14-17]. In the context of neurodegenerative disorders, MRI is crucial for identifying specific patterns of brain atrophy and structural degradation. For example, in Alzheimer's disease, significant volume reduction in areas such as the hippocampus and entorhinal cortex is often associated with disease progression. MRI-based volumetric analysis has become a critical tool for tracking these changes longitudinally, offering insight into disease mechanisms and the effects of potential treatments. MRI also plays an important role in identifying lesions and structural abnormalities in multiple sclerosis (MS), where white matter lesions are hallmarks of the disease and are used to monitor disease activity. Moreover, MRI can identify structural differences in psychiatric disorders like schizophrenia, where reductions in gray matter volume and cortical thickness have been consistently reported in specific regions. These structural markers are invaluable for understanding brain disorders, differentiating between disease states, and potentially identifying early biomarkers for high-risk populations.

Functional Magnetic Resonance Imaging (fMRI)

Functional MRI (fMRI) is an essential tool for studying brain activity by measuring blood-oxygen-level-dependent (BOLD) signals, which serve as indirect indicators of neural activity. Unlike structural MRI, fMRI enables researchers to assess how different brain regions communicate during cognitive tasks or while the brain is at rest [18-20]. In psychiatric disorders, such as depression and schizophrenia, abnormal patterns of connectivity between brain regions have been observed, often aligning with symptoms of these disorders [21-23]. Resting-state fMRI, which captures brain activity in the absence of a specific task, has revealed consistent disruptions in functional networks such as the default mode network (DMN), which is associated with self-referential thought and mind-wandering, in disorders like major depressive disorder. Task-based fMRI, on the other hand, involves monitoring brain activity while subjects perform specific tasks, allowing researchers to study specific cognitive processes such as memory, attention, or emotion processing. For instance, in schizophrenia, task-based fMRI has demonstrated abnormalities in the prefrontal cortex during working memory tasks, which are thought to underlie some of the cognitive deficits seen in the disorder. This ability to examine dynamic changes in brain activity makes fMRI a powerful modality for exploring the functional aspects of brain disorders and identifying potential therapeutic targets.

Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT)

Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are molecular imaging techniques that allow researchers to visualize and measure metabolic and neurotransmitter activity in the brain [24-26]. These methods are particularly useful for neurodegenerative disorders where metabolic dysfunction is a primary feature. PET imaging, for example, uses radiotracers like fluorodeoxyglucose (FDG) to assess glucose metabolism, providing insights into brain regions that may be metabolically impaired in diseases such as Alzheimer's. Additionally, PET tracers targeting amyloid and tau proteins have been developed, allowing for direct visualization of these pathological markers in living patients with Alzheimer's disease, thereby aiding in diagnosis and staging. PET can also be used to study the dopaminergic system in Parkinson's disease by tracking dopamine receptors and transporters, offering insights into disease severity and progression. SPECT, though less commonly used than PET, is beneficial for examining blood flow patterns and neurotransmitter activity, especially in cases of epilepsy where identifying the seizure focus is crucial for treatment planning. By enabling visualization of molecular processes, PET and SPECT provide a unique window into the biochemical alterations that underlie brain disorders, offering valuable information for both research and clinical applications.

Diffusion Tensor Imaging (DTI)

Diffusion Tensor Imaging (DTI), a form of MRI, provides insights into the integrity and orientation of white matter tracts in the brain by measuring the diffusion of water molecules along these fibers. In DTI, parameters such as fractional anisotropy (FA) and mean diffusivity (MD) reflect the organization and density of white matter, offering biomarkers for assessing connectivity within the brain. This technique is particularly valuable in disorders where connectivity disruptions are prominent, such as schizophrenia, autism spectrum disorder, and traumatic brain injury. For example, reduced FA values in white matter tracts connecting the frontal and temporal lobes have been observed in patients with schizophrenia, which may relate to the cognitive and functional impairments associated with the

DOI: 10.54756/IJSAR.2024.15

disorder. In multiple sclerosis, DTI allows for the detection of microstructural white matter changes beyond visible lesions on conventional MRI, offering an early indicator of disease activity and progression. Furthermore, DTI is used to examine brain connectivity in autism spectrum disorders, where differences in white matter integrity in pathways related to social processing have been linked to symptom severity. By mapping the brain's connectivity pathways, DTI enables researchers to study how structural connections are altered in brain disorders, advancing our understanding of the neural basis of these conditions. [27-28]

2.2. Quantitative Imaging and Feature Extraction

Quantitative imaging has transformed brain imaging by enabling the extraction of measurable data from images, moving beyond traditional, visually interpreted assessments. This shift allows for a more objective analysis of brain structure and function, capturing subtle changes that may be crucial for early diagnosis and monitoring of brain disorders. Key quantitative metrics include cortical thickness and regional brain volumes, both essential in assessing neurodegenerative diseases like Alzheimer's, where thinning of the cortex and volume loss in the hippocampus signal disease progression. White matter integrity metrics, derived from Diffusion Tensor Imaging (DTI), such as fractional anisotropy (FA), reveal disruptions in brain connectivity often seen in disorders like schizophrenia and autism spectrum disorders. These metrics provide insight into brain network integrity and communication pathways, helping to uncover structural deficits underlying symptoms [29]. Additionally, brain connectivity measures from fMRI data assess functional synchronization between brain regions, revealing network disruptions in psychiatric disorders like depression and schizophrenia. Graph theory-based measures allow researchers to map the brain's network organization, linking altered connectivity patterns with clinical symptoms. [30]

2.3. Volumetric Analysis and Cortical Thickness

Volumetric analysis and cortical thickness measurements are critical components of quantitative brain imaging, offering insights into structural changes associated with various brain disorders. Volumetric analysis involves measuring the volume of specific brain regions to detect atrophy or abnormal growth, which can serve as indicators of disease progression or diagnosis. For example, in Alzheimer's disease, reduced volumes in the hippocampus and entorhinal cortex are among the earliest signs of neurodegeneration and are closely linked to cognitive decline. These measurements have become essential for assessing disease severity and tracking changes over time, providing valuable information for both research and clinical applications. [31]

Cortical thickness, on the other hand, reflects the thickness of the cerebral cortex and has proven to be a reliable marker in both neurodegenerative and psychiatric conditions. In disorders like schizophrenia, reductions in cortical thickness have been observed in regions associated with cognitive and emotional processing, such as the prefrontal cortex. Cortical thinning in these areas may underlie the cognitive deficits characteristic of the disorder, offering a structural correlate to the symptoms experienced by patients. Additionally, measuring cortical thickness can provide insights into normal aging, distinguishing between age-related changes and pathological alterations, which is crucial for early diagnosis. [32]

2.4. Connectivity Analysis in Brain Networks

Connectivity analysis has become a central focus in understanding brain disorders, providing insights into how different regions of the brain communicate and function as interconnected networks. This approach explores both structural and functional connectivity [33]. Structural connectivity refers to the physical connections between brain regions, typically mapped using Diffusion Tensor Imaging (DTI), while functional connectivity examines the synchronization of activity between regions, often assessed through functional MRI (fMRI). In psychiatric disorders, disruptions in functional connectivity across specific networks have been linked to symptoms and cognitive deficits. For instance, the default mode network (DMN)—involved in self-referential and mind-wandering activities—often shows abnormal connectivity in disorders like depression and schizophrenia. Similarly, the executive control network, crucial for decision-making and cognitive control, may show reduced connectivity in individuals with attention-deficit/hyperactivity disorder (ADHD). These network disruptions highlight the role of impaired connectivity in the clinical manifestations of brain disorders, providing a neural basis for understanding these symptoms.

DOI: 10.54756/IJSAR.2024.15

Quantitative analysis of connectivity uses graph theory metrics, such as node strength, clustering coefficients, and path length, which help map the brain's network organization. By applying these metrics, researchers can visualize and measure how information flows within the brain and identify areas where connectivity is altered. For example, decreased connectivity in the prefrontal and limbic regions has been associated with cognitive and emotional regulation deficits in various disorders, while increased connectivity in some regions may suggest compensatory mechanisms or maladaptive reorganization. Connectivity analysis offers an objective way to evaluate brain function and establish biomarkers that may predict treatment responses or disease progression. By identifying these connectivity patterns, researchers and clinicians can gain a more nuanced understanding of how brain disorders disrupt communication networks, potentially leading to more targeted therapeutic strategies. As such, connectivity analysis in brain networks is a vital tool in advancing neuroimaging and enhancing our understanding of complex brain disorders.

2.5. Radiomics and Imaging Biomarkers

Radiomics is a rapidly evolving field within medical imaging that focuses on extracting high-dimensional quantitative features from images, transforming visual data into a comprehensive set of measurable attributes. By analyzing these features, radiomics enables the identification of unique patterns that may serve as biomarkers for brain disorders. Radiomics has particular relevance in brain imaging, as it can reveal subtle differences in texture, shape, and intensity that are difficult to detect through traditional qualitative assessment. This approach has opened new avenues for understanding disease processes and identifying non-invasive imaging biomarkers that aid in diagnosis, prognosis, and monitoring. [34-36]

Radiomic features provide detailed information on brain tissue characteristics. Texture analysis, for instance, captures variations in pixel intensity, revealing tissue heterogeneity associated with certain brain tumors or neurodegenerative conditions. Shape descriptors can highlight changes in brain structure that may accompany disease progression, while intensity features provide insights into metabolic activity or abnormal tissue density. By converting these imaging characteristics into quantifiable data, radiomics allows for a more nuanced assessment of brain changes, often correlating these features with clinical outcomes. The search for reliable imaging biomarkers in radiomics has shown promise for predicting disease progression and treatment response in various brain disorders. In Alzheimer’s disease, radiomic analysis of MRI scans can identify specific texture and shape patterns in the hippocampus that correlate with disease severity, providing a biomarker that supports early diagnosis. Similarly, in brain cancer, radiomics can differentiate between tumor types and predict treatment response, assisting in personalized treatment planning. For psychiatric disorders, radionics may help identify structural or functional features linked to symptoms, providing insights into conditions like schizophrenia, where imaging biomarkers could enhance diagnostic precision.

Radiomics and imaging biomarkers are paving the way for precision medicine, where treatment can be tailored to individual patients based on their unique imaging profiles. By integrating radionics into clinical practice, clinicians may soon be able to use imaging biomarkers to make more informed decisions about treatment and monitor disease progression more accurately. This data-driven approach enhances the role of imaging in brain disorders, transforming medical images into a powerful tool for personalized care and advancing our understanding of complex neurological conditions.

3. CHALLENGES IN CURRENT IMAGING ANALYSIS

Despite the significant advancements in imaging analysis, several challenges continue to limit its clinical application and research progress. A primary obstacle is the variability in imaging data, which can arise from differences in scanners, protocols, and settings across imaging sites. For instance, even slight variations in MRI field strength or slice thickness can result in inconsistencies in volumetric measurements or signal intensities, impacting the reproducibility and comparability of results. This variability complicates the aggregation of multi-site data, which is increasingly necessary to ensure sufficiently large sample sizes for robust statistical analysis, especially in rare brain disorders.

Another challenge lies in the high-dimensional and complex nature of imaging data. Advanced imaging techniques produce vast amounts of data, often with thousands of potential features per scan. Analyzing this high-dimensional data requires sophisticated computational tools and methods, yet managing and interpreting such large datasets remains challenging. Additionally, the need for large, annotated datasets is critical in developing reliable imaging

DOI: 10.54756/IJSAR.2024.15

biomarkers and machine learning models for automated analysis. However, acquiring extensive, well-labeled imaging datasets can be difficult, as these are resource-intensive to produce and often limited by patient privacy regulations.

Data standardization and validation also pose challenges in imaging analysis. Although some imaging tools, such as FreeSurfer, have standardized certain analyses like cortical thickness measurements, achieving uniformity across different software platforms and imaging centers remains a struggle. Validating imaging biomarkers for clinical use requires rigorous testing to ensure that these markers are both accurate and clinically meaningful across diverse populations. Currently, few imaging biomarkers have been universally accepted or translated into clinical practice due to the complexities involved in their validation.

Finally, there are significant ethical and privacy concerns associated with large-scale imaging studies. Brain imaging data is highly sensitive, and maintaining patient confidentiality while sharing data across research sites is a critical issue. Ethical considerations around the use of AI-based imaging analysis, particularly regarding transparency and interpretability, also limit clinical adoption. For example, while deep learning methods can achieve impressive accuracy, their “black box” nature often makes it difficult to interpret how decisions are made, which raises concerns in a clinical setting where interpretability and transparency are essential.

4. CONCLUSION

Advancements in imaging analysis have greatly enhanced our ability to study brain disorders, providing detailed insights into brain structure, function, and connectivity. Techniques like volumetric analysis, connectivity mapping, and radiomics have become invaluable tools, offering new avenues for diagnosis and treatment monitoring across a range of conditions. Despite these strides, challenges such as data variability, high-dimensional complexity, and ethical concerns around data use remain. Addressing these issues through standardized protocols, shared datasets, and explainable AI will be crucial to fully realizing the potential of imaging analysis in clinical practice. With continued progress, these methods promise to transform our approach to diagnosing and managing brain disorders, paving the way for more personalized and effective care.

REFERENCES

[1] Fornito A, Zalesky A, Breakspear M. The connectomics of brain disorders. Nature Reviews Neuroscience. 2015 Mar;16(3):159-72.

[2] Liu J, Li M, Pan Y, Lan W, Zheng R, Wu FX, Wang J. Complex brain network analysis and its applications to brain disorders: a survey. Complexity. 2017;2017(1):8362741.

[3] Inguaggiato E, Sgandurra G, Cioni G. Brain plasticity and early development: Implications for early intervention in neurodevelopmental disorders. Neuropsychiatrie de l'Enfance et de l'Adolescence. 2017 Sep 1;65(5):299-306.

[4] Fornito A, Zalesky A, Breakspear M. The connectomics of brain disorders. Nature Reviews Neuroscience. 2015 Mar;16(3):159-72.

[5] Orouskhani M, Zhu C, Rostamian S, Zadeh FS, Shafiei M, Orouskhani Y. Alzheimer's disease detection from structural MRI using conditional deep triplet network. Neuroscience Informatics. 2022 Dec 1;2(4):100066.

[6] Dijkhuizen RM, Nicolay K. Magnetic resonance imaging in experimental models of brain disorders. Journal of Cerebral Blood Flow & Metabolism. 2003 Dec;23(12):1383-402.

[7] Afrazeh F, Ghasemi Y, Shomalzadeh M, Rostamian S. The Role of Imaging Data from Different Radiologic Modalities During the Previous Global Pandemic. International Journal of Applied Data Science in Engineering and Health. 2024 Jul 27;1(1):9-17.

[8] Frank, Y. and Pavlakis, S.G., 2001. Brain imaging in neurobehavioral disorders. *Pediatric neurology*, *25*(4), pp.278-287.

[9] de Oliveira AM, Paulino MV, Vieira AP, McKinney AM, da Rocha AJ, Dos Santos GT, Leite CD, Godoy LF, Lucato LT. Imaging patterns of toxic and metabolic brain disorders. Radiographics. 2019 Oct;39(6):1672-95.

DOI: 10.54756/IJSAR.2024.15

[10] Afrazeh F, Ghasemi Y, Abbasi H, Rostamian S, Shomalzadeh M. Neurological Findings Associated with Neuroimaging in COVID-19 Patients: A Systematic Review. International Research in Medical and Health Sciences. 2024 Jul 30;7(3):1-5.

[11] Kotrotsou A, Zinn PO, Colen RR. Radiomics in brain tumors: an emerging technique for characterization of tumor environment. Magnetic Resonance Imaging Clinics. 2016 Nov 1;24(4):719-29.

[12] Zhou M, Scott J, Chaudhury B, Hall L, Goldgof D, Yeom KW, Iv M, Ou Y, Kalpathy-Cramer J, Napel S, Gillies R. Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. American Journal of Neuroradiology. 2018 Feb 1;39(2):208-16.

[13] Yi Z, Long L, Zeng Y, Liu Z. Current advances and challenges in radiomics of brain tumors. Frontiers in Oncology. 2021 Oct 14;11:732196.

[14] Raichle ME, Mintun MA. Brain work and brain imaging. Annu. Rev. Neurosci.. 2006 Jul 21;29(1):449-76.

[15] Johnson, K.A., Fox, N.C., Sperling, R.A. and Klunk, W.E., 2012. Brain imaging in Alzheimer disease. *Cold Spring Harbor perspectives in medicine*, *2*(4), p.a006213.

[16] Chattopadhyay A, Maitra M. MRI-based brain tumour image detection using CNN based deep learning method. Neuroscience informatics. 2022 Dec 1;2(4):100060.

[17] Valverde JM, Imani V, Abdollahzadeh A, De Feo R, Prakash M, Ciszek R, Tohka J. Transfer learning in magnetic resonance brain imaging: A systematic review. Journal of imaging. 2021 Apr 1;7(4):66.

[18] Cattarinussi G, Bellani M, Maggioni E, Sambataro F, Brambilla P, Delvecchio G. Resting-state functional connectivity and spontaneous brain activity in early-onset bipolar disorder: a review of functional magnetic resonance imaging studies. Journal of Affective Disorders. 2022 Aug 15;311:463-71.

[19] Kragel PA, Han X, Kraynak TE, Gianaros PJ, Wager TD. Functional MRI can be highly reliable, but it depends on what you measure: A commentary on Elliott et al.(2020). Psychological Science. 2021 Apr;32(4):622-6.

[20] Vahedifard F, Liu X, Kocak M, Ai HA, Supanich M, Marathu KK, Adler S, Orouskhani M, Byrd S. Artificial Intelligence in Fetal Resting-State Functional MRI Brain Segmentation: A Comparative Analysis of 3D UNet, VNet, and HighRes-Net Models. arXiv preprint arXiv:2311.10844. 2023 Nov 17.

[21] Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. The Lancet Psychiatry. 2020 Dec 1;7(12):1064-74.

[22] Podwalski P, Szczygieł K, Tyburski E, Sagan L, Misiak B, Samochowiec J. Magnetic resonance diffusion tensor imaging in psychiatry: a narrative review of its potential role in diagnosis. Pharmacological Reports. 2021 Feb;73(1):43-56.

[23] Rahmani A, Norouzi F, Machado BL, Ghasemi F. Psychiatric Neurosurgery with Advanced Imaging and Deep Brain Stimulation Techniques. International Research in Medical and Health Sciences. 2024 Nov 1;7(5):63-74.

[24] Norgaard M, Matheson GJ, Hansen HD, Thomas A, Searle G, Rizzo G, Veronese M, Giacomel A, Yaqub M, Tonietto M, Funck T. PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. Scientific data. 2022 Mar 2;9(1):65.

[25] Davis KM, Ryan JL, Aaron VD, Sims JB. PET and SPECT imaging of the brain: history, technical considerations, applications, and radiotracers. InSeminars in Ultrasound, CT and MRI 2020 Dec 1 (Vol. 41, No. 6, pp. 521-529). WB Saunders.

[26] Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB. PET imaging of neuroinflammation in neurological disorders. The Lancet Neurology. 2020 Nov 1;19(11):940-50.

DOI: 10.54756/IJSAR.2024.15

[27] ElNakieb Y, Ali MT, Elnakib A, Shalaby A, Soliman A, Mahmoud A, Ghazal M, Barnes GN, El-Baz A. The role of diffusion tensor MR imaging (DTI) of the brain in diagnosing autism spectrum disorder: promising results. Sensors. 2021 Dec 7;21(24):8171.

[28] Videtta G, Squarcina L, Rossetti MG, Brambilla P, Delvecchio G, Bellani M. White matter modifications of corpus callosum in bipolar disorder: A DTI tractography review. Journal of Affective Disorders. 2023 Oct 1;338:220-7.

[29] Magalhães TN, Casseb RF, Gerbelli CL, Pimentel-Siva LR, Nogueira MH, Teixeira CV, Carletti AF, de Rezende TJ, Joaquim HP, Talib LL, Forlenza OV. Whole-brain DTI parameters associated with tau protein and hippocampal volume in Alzheimer's disease. Brain and behavior. 2023 Feb;13(2):e2863.

[30] Wang Z, Xin J, Wang Z, Yao Y, Zhao Y, Qian W. Brain functional network modeling and analysis based on fMRI: a systematic review. Cognitive neurodynamics. 2021 Jun;15:389-403.

[31] Pomponio R, Erus G, Habes M, Doshi J, Srinivasan D, Mamourian E, Bashyam V, Nasrallah IM, Satterthwaite TD, Fan Y, Launer LJ. Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. NeuroImage. 2020 Mar 1;208:116450.

[32] Madre M, Canales-Rodríguez EJ, Fuentes-Claramonte P, Alonso-Lana S, Salgado-Pineda P, Guerrero-Pedraza A, Moro N, Bosque C, Gomar JJ, Ortíz-Gil J, Goikolea JM. Structural abnormality in schizophrenia versus bipolar disorder: a whole brain cortical thickness, surface area, volume and gyrification analyses. NeuroImage: Clinical. 2020 Jan 1;25:102131.

[33] Younger, E.F., Ellis, E.G., Parsons, N., Pantano, P., Tommasin, S., Caeyenberghs, K., Benito-León, J., Romero, J.P., Joutsa, J. and Corp, D.T., 2023. Mapping essential tremor to a common brain network using functional connectivity analysis. *Neurology*, *101*(15), pp.e1483-e1494.

[34] Ding Y, Zhao K, Che T, Du K, Sun H, Liu S, Zheng Y, Li S, Liu B, Liu Y, Alzheimer's Disease Neuroimaging Initiative. Quantitative radiomic features as new biomarkers for Alzheimer's disease: An amyloid PET study. Cerebral Cortex. 2021 Aug;31(8):3950-61.

[35] Chen Q, Xia T, Zhang M, Xia N, Liu J, Yang Y. Radiomics in stroke neuroimaging: techniques, applications, and challenges. Aging and disease. 2021 Feb;12(1):143.

[36] Shi D, Zhang H, Wang G, Yao X, Li Y, Wang S, Ren K. Neuroimaging biomarkers for detecting schizophrenia: a resting-state functional MRI-based radiomics analysis. Heliyon. 2022 Dec 1;8(12).

DOI: 10.54756/IJSAR.2024.15